March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...
Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...
VOYAGER THERAPEUTICS ($VYGR) posted quarterly earnings results on Tuesday, March 11th. The company reported earnings of -$0.59 per share, missing estimates of -$0.37 ...
VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...
Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the ...
2d
Zacks.com on MSNVoyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...
Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results